Thr887
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr887  -  p300 (human)

Site Information
PPPRQTPtPPTTQLP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4331003

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 ) , mutation of modification site ( 4 )
Disease tissue studied:
breast cancer ( 2 ) , breast ductal carcinoma ( 2 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 3 , 4 ) , breast ( 1 , 2 ) , COS (fibroblast) ( 4 )

Upstream Regulation
Regulatory protein:
AML1 (human) ( 4 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

3

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

4

Wee HJ, Voon DC, Bae SC, Ito Y (2008) PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 112, 3777-87
18695000   Curated Info